Clarithromycin Resistance Gene in Helicobacter pylori
Clarithromycin resistance in Helicobacter pylori is one of the main challenges in treating the gastric infection caused by this bacterium. Clarithromycin is one of the most widely used antibiotics in eradication regimens, and rising bacterial resistance has directly impacted treatment success rates, requiring more accurate and personalized diagnostic approaches.
Helicobacter pylori is a gram-negative bacterium that colonizes the human gastric mucosa and is associated with chronic gastritis, peptic ulcer disease, and gastric cancer.
Clarithromycin resistance occurs mainly due to point mutations in the bacterium’s 23S rRNA gene. These mutations alter the antibiotic binding site on the bacterial ribosome, reducing its effectiveness and preventing inhibition of protein synthesis.
The mutations most frequently associated with resistance include:
A2142G
A2142C
A2143G
The presence of these genetic changes is directly associated with therapeutic failure in regimens that use clarithromycin.
The prevalence of clarithromycin resistance varies by geographic region and is higher in areas with frequent macrolide use. Increasing resistance has led to revisions of clinical guidelines, which recommend susceptibility testing whenever possible, especially in regions with high therapeutic failure rates.
Prior identification of resistance is essential to avoid ineffective treatments, unnecessary antibiotic exposure, and further development of resistance.
Patients infected with resistant strains present:
Higher likelihood of failure of initial treatment
Need for alternative treatment regimens
Higher risk of persistent infection
Possible progression to complications such as ulcer and gastric neoplasia
An empirical approach, without identifying resistance, can compromise therapeutic effectiveness and increase clinical costs.
Detection of clarithromycin resistance can be performed by phenotypic methods (culture and susceptibility testing); however, these methods are slower and technically demanding.
Real-Time PCR enables:
Direct identification of H. pylori DNA
Specific detection of resistance-associated mutations
Fast, highly sensitive results
Use in clinical samples, including gastric biopsies
Molecular analysis provides decisive support for selecting the most appropriate treatment regimen.
Clarithromycin resistance is considered the main factor in failure of classic triple therapy for eradication of H. pylori. Incorporating molecular testing before starting treatment helps to:
Personalized therapy
Increase eradication rates
Reduce inappropriate antibiotic use
Control antimicrobial resistance
The Bioperfectus Real-Time PCR Kit for Detection of the Clarithromycin Resistance Gene in Helicobacter pylori was developed to quickly and accurately identify the main mutations in the 23S rRNA gene associated with clarithromycin resistance.
Specific detection of mutations A2142G, A2142C, and A2143G
High molecular sensitivity and specificity
Fast results, reducing time to treatment decision
Support for selecting the most effective antibiotic regimen
Reduced therapeutic failure rate
By incorporating the Bioperfectus Kit into laboratory routine, clinics and hospitals can offer a diagnostic approach based on molecular evidence, enabling targeted treatment and a higher success rate in eradication of H. pylori.
Early detection of resistance not only improves clinical outcomes, but also contributes to rational antimicrobial use and the global fight against bacterial resistance.
